NCT01112384 - A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2010

Primary Completion Date

January 21, 2013

Study Completion Date

January 16, 2014

Conditions

Metastatic Sarcoma

Interventions

DRUG

SB939

Given orally 3 times per week

Trial Locations (8)

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

BCCA - Vancouver Cancer Centre, Vancouver

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

London Regional Cancer Program, London

Ottawa Health Research Institute - General Division, Ottawa

Univ. Health Network-Princess Margaret Hospital, Toronto

McGill University - Dept. Oncology, Montreal